Grading Ductal Carcinoma In Situ (DCIS) of the Breast – What’s Wrong with It?

Gábor Cserni, Anita Sejben

Research output: Contribution to journalReview article

1 Citation (Scopus)


Ductal carcinoma in situ of the breast is a non-obligate precursor of invasive breast cancer, and at its lower risk end might not need treatment, a hypothesis tested in several currently running randomized clinical trials. This review describes the heterogeneity of grading ductal carcinoma in situ (DCIS). First it considers differences between low and high grade DCIS, and then it looks at several grading schemes and highlights how different these are, not only in the features considered for defining a given grade but also in their wording of a given variable seen in the grade in question. Rather than being fully comprehensive, the review aims to illustrate the inconsistencies. Reproducibility studies on grading mostly suggestive of moderate agreement on DCIS differentiation are also illustrated. The need for a well structured, more uniform and widely accepted language for grading DCIS is urged to avoid misunderstanding based misclassifications and improper treatment selection.

Original languageEnglish
Pages (from-to)665-671
Number of pages7
JournalPathology and Oncology Research
Issue number2
Publication statusPublished - Apr 1 2020


  • Breast cancer
  • Ductal carcinoma in situ
  • Grade

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Grading Ductal Carcinoma In Situ (DCIS) of the Breast – What’s Wrong with It?'. Together they form a unique fingerprint.

  • Cite this